Eraxis Injection, Powder, Lyophilized, For Solution
Product Images NDC 0049-0116
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Eraxis (NDC 0049-0116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Roerig, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Logo (Eraxis 02)
Principal Display Panel (50 mg Vial Label)
This is a description of how to properly store and use Eraxis®, an anidulafungin injection. The vial should be refrigerated but not frozen, and must be reconstituted with 15 mL of sterile water for injection. Each L contains 3.3 mg of anidulafungin after reconstitution, and it should be further diluted with 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP as instructed in the Prescribing Information prior to intravenous infusion. The usual dosage should be determined by the prescribing information, and the solution should be used within 24 hours. The packaging includes one single-dose vial and is for intravenous infusion only. Eraxis® is distributed by Roerig division of Pfizer Inc in New York, NY and requires a prescription.*
Principal Display Panel (50 mg Vial Carton)
Eraxis® 50mg is a medication for injection for intravenous infusion only. Each unit pack contains a single-dose vial of 50mg with 15toril. Eraxis® must be reconstituted with 16 mL of sterile water for injection. After reconstitution, each mL contains 3.3 mg anidulafungin. Further dilution with 5% Dextrose Injection, USP or 0.9% Sodium Chiorid Injection, USP should be done as instructed in the prescribing information prior to intravenous infusion. The solution in the vial should be used within 24 hours, and the unused portion should be discarded. The usual dosage and other relevant details are mentioned in the prescribing information. The medication should be stored at a temperature of 2-8 °C, and it is not to be frozen. The text also contains the distributer of the medication, Roerig Division of Pfizer Inc. Eraxis® is a trademark of Vicuron Pharmaceuticals Inc., Pfizer Company.*
Principal Display Panelpanel (100 mg Vial Label)
This is a set of instructions for the proper storage, reconstitution, and usage of Eraxis® - an antifungal medication indicated for intravenous infusion only. The text advises to store the vial in a refrigerator between 2-8°C, not to freeze it, and to use the reconstituted solution within 24 hours. After reconstitution with 30mL of sterile water, the solution must be diluted with 5% Dextrose Injection or 0.9% Sodium Chloride Injection before intravenous infusion as per the prescribing information. The product contains 100mg/vial of anidulafungin. The text also provides the name of the distributor, Roerlg division of Pz Inc.*
Principal Display Panel (100 mg Vial Carton)
Eraxis® 100 mg (anidulafungin) is a medication that comes in a sterile single-dose vial for intravenous infusion only. The unit pack contains fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 m), tartaric acid (11.2mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. The medication must be reconstituted with 30 mL of sterile water for injection and should be further diluted with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP according to the prescribing information prior to intravenous infusion. The usual dosage depends on the medical condition, and the prescribing information should be followed.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.